Cabotegravir is an antiretroviral integrase inhibitor used for HIV treatment and prevention, available as oral and long-acting injectable formulations. It is marketed under brand names including Vocabria and Apretude. Regulatory approvals include HIV-1 treatment combination use and pre-exposure prophylaxis indications.
South Africa is working to identify local manufacturers for lenacapavir, a twice-yearly injectable HIV prevention drug that showed near-perfect efficacy in clinical trials. Kenya has already received 21,000 doses of the medication.
Zimbabwe began rolling out lenacapavir, a twice-yearly injectable HIV prevention drug, on February 19 in Epworth. The program will initially target more than 46,000 people at high risk across 24 sites nationwide.
Phase 3 LATITUDE trial shows monthly cabotegravir-rilpivirine injections cut regimen failure risk by 18.4 percentage points compared to daily oral ART in HIV patients with documented adherence difficulties.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05996471 |
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03149848 |
Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects |
COMPLETED | PHASE1 |
| NCT02462772 |
Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa |
WITHDRAWN | PHASE2 |
